In a pregnant woman diagnosed with gestational diabetes mellitus, when are repeat 75‑g oral glucose tolerance tests indicated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Follow-Up OGTT for Gestational Diabetes

Women diagnosed with gestational diabetes mellitus should undergo a 75-g oral glucose tolerance test at 4-12 weeks postpartum to screen for persistent diabetes or prediabetes, and then continue lifelong screening at least every 3 years. 1

Postpartum Testing (Primary Indication for Repeat OGTT)

The most critical repeat OGTT occurs in the postpartum period:

  • All women with GDM must be reevaluated at 4-12 weeks postpartum using a 75-g OGTT with clinically appropriate non-pregnancy diagnostic criteria to detect persistent diabetes or prediabetes 1, 2, 3, 4, 5
  • This postpartum testing is mandatory because women with GDM have a 3.4-fold increased risk of developing type 2 diabetes later in life 2
  • Use standard WHO diagnostic criteria for the postpartum OGTT (not pregnancy-specific thresholds) 3, 4, 5

Long-Term Surveillance

Beyond the immediate postpartum period, ongoing monitoring is essential:

  • Lifelong screening for diabetes or prediabetes should occur at least every 3 years in women with normal postpartum glucose tolerance 1, 2
  • Some guidelines recommend assessment every 2-3 years using fasting glucose, random glucose, HbA1c, or optimally a repeat OGTT 4, 5
  • Women found to have prediabetes should receive intensive lifestyle interventions or metformin to prevent progression to diabetes 1

Repeat OGTT During Pregnancy (Third Trimester)

While not routinely recommended, repeat OGTT during pregnancy may be indicated in specific circumstances:

  • Consider repeating the OGTT in the third trimester if clinical signs or symptoms suggestive of GDM develop after an initial negative screening at 24-28 weeks 6
  • Research shows that approximately 23.5% of women who undergo a second OGTT in the third trimester after initial negative results will be diagnosed with GDM 6
  • Specific indications for third-trimester repeat testing include:
    • Evidence of excessive fetal growth (macrosomia) on ultrasound 6
    • History of prior GDM (odds ratio 2.6 for positive second OGTT) 6
    • Higher glucose values on the index OGTT, even if below diagnostic thresholds (fasting ≥4.8 mmol/L or 2-hour ≥6.5 mmol/L) 6
    • New onset glucosuria or other clinical symptoms of diabetes 3, 4, 5

Important Clinical Considerations

Common pitfalls to avoid:

  • Do not assume that women with GDM will automatically return to normal glucose tolerance postpartum—active follow-up and testing are required 1
  • Do not rely solely on fasting glucose or HbA1c for postpartum screening; the 75-g OGTT is the recommended test as it can detect impaired glucose tolerance that other tests might miss 1, 4
  • Do not delay postpartum testing beyond 12 weeks, as this is a critical window for reclassifying glucose tolerance status 1, 4, 5

Special populations:

  • In women with a history of bariatric surgery, OGTT is not recommended due to risk of postprandial hypoglycemia; use alternative glucose assessment methods 4, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnosis and Management of Gestational Diabetes Mellitus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Gestational diabetes mellitus].

Acta medica Austriaca, 2004

Research

[Gestational diabetes mellitus (Update 2023)].

Wiener klinische Wochenschrift, 2023

Research

[Gestational diabetes mellitus (Update 2019)].

Wiener klinische Wochenschrift, 2019

Research

Repeated oral glucose tolerance tests in women at risk for gestational diabetes mellitus.

European journal of obstetrics, gynecology, and reproductive biology, 2019

Related Questions

What is the management plan for a 34-week pregnant woman with gestational diabetes mellitus (GDM), oral glucose tolerance test (OGTT) result of 230 mg/dL, and significant glycosuria (urine sugar 4+), should she be admitted?
Is a postpartum (after pregnancy) woman, approximately three months postpartum with a history of possible gestational diabetes mellitus (GDM), diagnosed with diabetes mellitus based on a glucose tolerance test result of 138 mg/dL at two hours?
How to manage a 28-week primigravida (first-time pregnant woman) at 37 weeks gestation with a random blood sugar level of 213 mg/dl at 7 am, indicating hyperglycemia?
Is a 1-hour Oral Glucose Tolerance Test (OGTT) result of 212 mg/dL at 11 weeks gestation indicative of gestational diabetes mellitus (GDM) or type 2 diabetes?
What care is recommended for a pregnant woman with a Body Mass Index (BMI) of 24, no history of Gestational Diabetes Mellitus (GDM), and a normal pregnancy?
In a 61-year-old woman taking an estradiol transdermal patch 0.025 mg twice weekly, oral progesterone 100 mg, Cordone 25 mg, atenolol 25 mg, and venlafaxine extended‑release 75 mg with a blood pressure of 140/90 mm Hg, what additional medication should be added to control her hypertension?
What patient education should be provided for a patient with a concussion?
What is the appropriate management of a laceration involving the knee joint region?
What is the recommended immediate work‑up and management for cavernous sinus syndrome?
What is the recommended approach to bridge a patient from an intravenous insulin infusion to subcutaneous insulin therapy?
How can I perform a landmark‑guided transversus abdominis plane (TAP) block for postoperative analgesia in an adult undergoing lower‑mid abdominal surgery (e.g., appendectomy, cesarean section, hernia repair) when there is no infection at the injection site, no uncontrolled coagulopathy, and no allergy to local anesthetics, and what are the contraindications?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.